We serve Chemical Name:4-Amino-2-fluorobenzamide CAS:609783-45-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Amino-2-fluorobenzamide
CAS.NO:609783-45-1
Synonyms:4-amino-2-fluoro-benzamide
Molecular Formula:C7H7FN2O
Molecular Weight:154.14200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:69.11000
Exact Mass:154.05400
LogP:1.78830
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-amino-2-fluoro-benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-amino-2-fluoro-benzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-amino-2-fluoro-benzamide Use and application,4-amino-2-fluoro-benzamide technical grade,usp/ep/jp grade.
Related News: The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 4-Amino-2-fluorobenzamide manufacturer The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion. 4-Amino-2-fluorobenzamide supplier The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. 4-Amino-2-fluorobenzamide vendor The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 4-Amino-2-fluorobenzamide factory The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.
